- Home
- CBRE vs HLN Comparison
CBRE vs HLN Comparison
Compare CBRE & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- HLN
- Stock Information
- Founded
- CBRE 1906
- HLN 2022
- Country
- CBRE United States
- HLN United Kingdom
- Employees
- CBRE N/A
- HLN N/A
- Industry
- CBRE Real Estate
- HLN Package Goods/Cosmetics
- Sector
- CBRE Finance
- HLN Consumer Discretionary
- Exchange
- CBRE Nasdaq
- HLN Nasdaq
- Market Cap
- CBRE 40.1B
- HLN 47.1B
- IPO Year
- CBRE 2004
- HLN N/A
- Fundamental
- Price
- CBRE $130.21
- HLN $9.40
- Analyst Decision
- CBRE Buy
- HLN Strong Buy
- Analyst Count
- CBRE 6
- HLN 2
- Target Price
- CBRE $116.83
- HLN $10.48
- AVG Volume (30 Days)
- CBRE 2.0M
- HLN 6.0M
- Earning Date
- CBRE 10-24-2024
- HLN 08-01-2024
- Dividend Yield
- CBRE N/A
- HLN 1.67%
- EPS Growth
- CBRE 66.15
- HLN N/A
- EPS
- CBRE 3.10
- HLN 0.18
- Revenue
- CBRE $34,313,000,000.00
- HLN $15,065,004,686.00
- Revenue This Year
- CBRE $13.11
- HLN $2.92
- Revenue Next Year
- CBRE $9.81
- HLN $2.80
- P/E Ratio
- CBRE $41.96
- HLN $25.87
- Revenue Growth
- CBRE 10.00
- HLN N/A
- 52 Week Low
- CBRE $76.63
- HLN $7.89
- 52 Week High
- CBRE $137.93
- HLN $10.80
- Technical
- Relative Strength Index (RSI)
- CBRE 51.32
- HLN 34.42
- Support Level
- CBRE $133.73
- HLN $9.10
- Resistance Level
- CBRE $137.93
- HLN $9.86
- Average True Range (ATR)
- CBRE 3.38
- HLN 0.10
- MACD
- CBRE -0.42
- HLN -0.03
- Stochastic Oscillator
- CBRE 22.90
- HLN 34.71
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.